Subscribe via RSS

Tags: barclays capitalRemove, convertibleRemove, pharmaceuticalsRemove

Equities
Aurobindo Pharma CB uses rare premium structure
Strong expansion story allows company to fix conversion price on 25% of the deal in 12 months time; investors compensated by high yield and high bond floor.
By Anette Jönsson | 23 April 2006
| Next »
Tag Filters
MOST READ
Polls
How much value do investment banks bring to IPOs?
   |   View results
$$$$$
  15%
 
$$$
  21%
 
$
  64%
TOTAL VOTES: 92

 
View previous polls »
LATEST FROM AsianInvestor
Latest headlines from AsianInvestor
More from AsianInvestor »
WEBCASTS
On Demand Webcasts
View all webcasts »
Tables
Latest League Tables » Dealogic
DCM | ECM | M&A | Fees
Debt Pipeline »
Equity Pipeline »
Magazine
FinanceAsia Magazine
FinanceAsia
May 2012